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Systemic Sclerosis (Scleroderma, SSc) is a disease of unknown etiology characterized by widespread vasculopathy and extracellular
matrix deposition leading to ﬁbrosis and autoimmune processes. Digital ischemia (digital ulcers (DUs)) is the hallmark of SSc-
related vasculopathy and is characterized by endothelial dysfunction leading to intimal proliferation and thrombosis. It happens
frequently (30% of the patients each year) and it is associated with signiﬁcant morbidity. This paper summarizes the current
information regarding pathogenesis, deﬁnitions, management, and exploratory therapies in DUs associated with SSc.
1.Introduction
The subject of digital ischemia in systemic sclerosis is
complex and poses various challenges in terms of diag-
nosis, classiﬁcation, risk factors, therapy, and morbidity.
Raynaud’s phenomenon (RP), characterized by exaggerated
but reversible vasospasm in response to cold or stress, is the
presenting symptom in over 90% of the patients with SSc
[1]. RP is the most common manifestation of the SSc-related
endothelialdysfunctionanddigitalulcers(DUs)areaclinical
manifestation of SSc-related vasculopathy.
D i gi t a lu l c e r si nS S ca r ed e ﬁ n e da sn e c r o t i cl e s i o n so c c u r -
ring at the distal aspects of ﬁngers or toes. The underlying
phenomenon is compromise of the arterial lumen which
occurs as a combination of 2 major contributing factors:
(1) vascular wall structural (intimal proliferation) and
functional (overproduction of vasoconstrictors)
abnormalities,
(2) a variable degree of intraluminal thrombosis.
DUs are painful, heal slowly, and lead to a great deal of
disability. Due to the inadequate blood supply and break in
the skin, the ischemic lesions are prone to infection, loss
of digital tissue, and progression to gangrene that requires
amputation.
Currently, there is no oﬃcial algorithm for diagnosis and
therapy of digital ischemia in SSc. A conventional thera-
peutic approach to digital lesions should include vasoactive
medications, antiplatelet agents, antibiotics as needed, and
analgesia. The response to vasodilators in patients with SSc
is variable and often disappointing. There is a visible need
for strategies to facilitate healing of the DUs and to prevent
occurrence of new ones.
2.Deﬁnition ofDigitalUlcersinSSc
The correct diagnosis of DUs is instrumental both in
clinical practice and in clinical trials focused on digital
ischemia. Almost all SSc patients experience involvement
of their hands: ischemic lesions, local infection, calcinosis,
and traumatic ulcers occurring in areas aﬀected by ﬂexion
contractions. Although the SSc-related vasculopathy aﬀects
the healing time of all the acral lesions, it is crucial to
clinically deﬁne the true ischemic lesion.
A recent study tested the intra- and interobserver vari-
ability in deﬁning DUs among clinicians with an interest
in scleroderma [2]. 50 individuals (mostly rheumatologists)
were shown pictures of various hand lesions and were asked
to qualify the lesions (“ulcer” versus “no ulcer”) and if
“ulcer”, to quantify it as “active” or “inactive”. Although
the intrarater reliability was high (average kappa value of
0.81), the interrater reliability was poor (kappa coeﬃcient2 International Journal of Rheumatology
Figure 1: True digital ulcer.
of 0.46), so individual examiners were consistent with
their assessment, while diﬀerent examiners disagreed. This
lack of agreement among rheumatologists who evaluate
digital lesions on a regular basis may have an impact on
interpretation of the results of clinical studies and more so
on initiating and maintaining treatment of DUs in clinical
practice.
One of the more precise deﬁnitions of SSc-DUs was
described in the RAPIDS-1 clinical trial [3]. The deﬁnition
was based on expert consensus and is currently used in
the majority of trials focused on DUs. Digital ulcers are
deﬁned as a denuded area with well demarcated borders,
involving loss of dermis and epidermis. They are located
on the volar surface of the ﬁngers, distal to the proximal
interphalangeal joints (Figure 1). The DUs do not occur
in the interphalangeal creases and should not be con-
fused with paronychia, areas with underlining calcinosis,
or traumatic lesions located on the dorsum of the hands
(PIPs or MCPs) (Figure 2). A recent article focused on
deﬁnitions and subclasses of SSc-DUs (1614 digital lesions
were prospectively observed over 4 years) [4]. The digital
lesions were classiﬁed as digital pitting scars (DPSs), DUs,
calcinosis, and gangrene. Clinical characteristics, depth
(superﬁcial, intermediate, and deep) and time to healing
of the lesions were recorded. The overwhelming majority
of digital lesions, were DUs and DPSs (92.7%). The digital
lesions were located more frequently on the second and
third digit and mostly on the ﬁngertip area. Presence of
calcinosis, wet or dry necrosis, and infection signiﬁcantly
delayed the time to healing. In this study, the deﬁnition
used for the “pure” DUs matched the one from the RAPIDS
studies and the DUs had a distinct natural history. The
authors concluded that a precise classiﬁcation of the subtype
of digital lesion is important when diﬀerent therapies
are entertained: DUs due to calcinosis may not be as
responsive to vasodilators as a purely ischemic DUs would
be.
Figure 2: Traumatic ulcer.
3. Pathogenesis of DigitalUlcers in SSc
The initial trigger in SSc-related vasculopathy is unknown.
It is believed that smooth muscle cells migrate into the
intimal layer of the microvasculature and diﬀerentiate into
myoﬁbroblasts that secrete collagen and an other extracel-
lular matrix. This process leads to a ﬁxed narrowing of the
intravascularlumenwhichhindersthebloodﬂowandcauses
chronic tissue ischemia. Histological studies showed that
18 (79%) of the 23 evaluable biopsies of digital arteries of
patients with SSc had greater than 75% luminal narrowing
[5].
Aside from the structural change, the endothelial cells
are perturbed, possibly through ischemia-reperfusion injury
or an autoimmune insult [6] leading to an increased
production of vasoconstrictors such as endothelin and an
underproduction of vasodilators such as prostacyclin and
nitric oxide. Another proposed mechanism of endothelial
injury is the presence of antiendothelial cell antibodies [7].
One other possible consequence of the endothelial damage
is platelet activation with release of thromboxane [8]w h i c h
leads to intraluminal thrombosis.
4. NaturalHistory of DigitalUlcers inSSc:
Incidence, Risk Factors,and ClinicalImpact
Various studies have revealed that 15%–25% of SSc patients
have active DUs [9] and 35%–50% had a history of DUs
[10]. DUs are painful, disabling, and associated with a
variable rate of progression to gangrene or infection leading
to amputation. A particularly emergent situation is the
ischemically threatened digit (Figure 3) due to the high rate
of need for surgical intervention.
Although a prospective registry of patients with SSc-DUs
is lacking, the available data from retrospective analysis [11,
12] outline the following risk factors for developing DUs:International Journal of Rheumatology 3
Figure 3: Ischemically threatened digit.
(1) male sex,
(2) presence of pulmonary hypertension and/or lower
DLCO,
(3) diﬀuse subset of the disease,
(4) early onset of SSc,
(5) presence of antitopoisomerase I antibodies (anti-
topo I),
(6) smoking.
Patients with DUs developed internal organ involvement 2-3
years earlier compared to patients without ulcers [12].
The use of nailfold videocapillaroscopy (NVC) may be
a novel tool useful to predict development of SSc-DUs: the
speciﬁcity and sensitivity were as high as 85.9% and 94.3%,
respectively [13].
Episodes of DUs tend to reoccur, with 66% of patients
having more than one episode and 50% having more than 2
episodes over a period of 7.26 years [14] despite the use of
vasodilators. In the same cohort, the ulcers occurred more
frequently in the second and third digits (II: 32.5%, III:
32.5%) and were equally distributed among both hands.
Thirty patients (67%) had critical ﬁnger ischemia at least
once, and 43% of patients received at least one course
of intravenous iloprost; 7% of patients underwent surgical
amputation.
The morbidity related to presence of DUs is signiﬁcant.
In the Pittsburgh database [15], the disability measured
by the Scleroderma HAQ (SHAQ) was signiﬁcantly greater
in patients with persistent DUs. Patients also had more
hospitalizations and more hospitalizations for antibiotics
than patients without DUs (16 versus 9%). The incidence of
gangrenous lesions was 11% and increased with the length of
time since the ﬁrst DUs, especially after 4 years. Data from
the Randomized Placebo-Controlled Study on Prevention of
DUs in SSc (RAPIDS-2) trial conducted in 188 patients with
active DUs reported the incidence of amputation to be 11%
(1-2%/patient-year of followup) [16].
A retrospective analysis of all the hospitalized cases due
to ischemically threatened digits (ITDs) over a period of 10
years in a tertiary care center identiﬁed 79 patients, of which
22.8% had SSc [17]. In that particular cohort, the rate of
amputation was 48.1%, and male sex, a history of previous
ITD, or ITD developed in the hospital were associated with a
higher rate of amputation.
5. Therapeutic Options for SSc-DigitalUlcers
The therapeutic approach in SSc-DUs poses multiple chal-
lenges. Ischemic DUs can be confused with DUs due to
trauma or calcinosis. There is disagreement about the diﬀer-
ence between active and nonactive ulcers. The pathogenesis
of SSc-DUs is complex, and it involves multiple pathways
which need to be addressed concomitantly. Pain and infec-
tion are common comorbidities that require supportive
therapy. Response to the instituted medical therapy needs
to be continuously assessed to detect the need for additional
drug therapies or to consider surgical options.
The available clinical trials for treatment of active SSc-
DUs, although largely negative, have contributed to our
knowledge about outcome measures in this disease [18].
The crude measurement of the depth and length of DUs
is not feasible due to the location of the ulcerations and
the associated pain. The only direct parameter remains the
absolute healing of the DUs, which includes an anatom-
ical (re-epithelialization of the area) and a physiological
(pain cessation) component. Other indirect parameters, like
instruments focusing on quality of life (HAQ) and function
of the hand (UKFS and the Michigan Hand Questionnaire)
require further validation studies.
TheDUstherapeuticapproachincludes:supportivemea-
sures, pharmacological interventions, and surgical options.
5.1. Supportive Therapies. Patients who develop SSc-DUs
must be educated to keep their whole body warm (not
just the hands) and to avoid direct trauma to the tips of
the digits. It is paramount for smokers to quit. All other
vasoconstrictors (cocaine, sympathomimetics) should be
discontinued.
Pain related to SSc-DUs is exquisite and lasts as long
as the DUs is active, which could be months. The intensity
of the DUs-related pain is signiﬁcant and could lead to
anxiety which potentially worsens the Raynaud’s symptoms
which in turn could contribute to a lengthier healing
process. Pain management should be instituted promptly
and adequately escalated. Although the nonsteroidal anti-
inﬂammatorydrugsareveryeﬃcient,theyshouldbeavoided
in favor of acetaminophen or opiates due to their vascular
side eﬀects. Since the cause of the pain is tissue ischemia, the
real solution is improving the oxygen delivery to the aﬀected
area.
Infections are common in SSc-DUs and heal slowly
because of the poor circulation. Clinicians should inspect
each ulcer carefully at each visit. Clinical clues to DUs4 International Journal of Rheumatology
infection are an increase in the amount of pain (and a
change of character to throbbing) and presence of purulent
discharge. Simple gram positive coverage is usually very
eﬃcient but broad coverage antibiotics might be used if the
ulcers are more extensive. Patients may require more than
one course of antibiotics.
If osteomyelitis is suspected, patients should be managed
by a multidisciplinary team that includes infectious disease
and orthopedic specialists. Intravenous antibiotics, hyper-
baric therapy, and surgical amputation may be helpful.
5.2. Pharmacological Therapies. The purpose of the DUs
treatment is to reduce their overall burden and impact
on quality of life. Aside from controlling the pain and
preventing infections, clinicians need to restore the hand
function, improve the digital circulation, and promote
healing of the existing DUs while preventing formation of
newulcers.DespitethesubstantialimpactthatSSc-DUshave
on function and quality of life, there is currently no accepted
therapy algorithm nor any FDA- approved therapies.
The treatment algorithm should mirror the pathogenesis
of SSc-DUs and should include antiplatelet agents and
vasoactive agents. It has become common practice that
patients with a history of DUs or an active DUs should take
at least a low dose of aspirin (81mg) daily. Clopidrogrel is
being used with or without aspirin for active DUs but there
are no published data on safety and overall eﬃcacy.
Vasoactive therapy includes the background therapy
for Raynaud’s Phenomenon (RP) and agents from a few
available classes that were shown to improve SSc-DUs or are
undergoing experimental trials. Potential therapies for SSc-
DUs will be outlined below by class.
5.2.1. Calcium Channel Blockers. Calcium channel blockers
(CCBs) are widely used for the treatment of primary and
secondary RP, reducing the severity of attacks by 35%
[19]. The eﬀect of CCB on SSc-DUs was reported in a
small 16-week randomized controlled trial that compared
oral nifedipine with intravenous iloprost: the mean number
of ulcers decreased (from 4.3 to 1.4) but there were no
physiological changes in the microvasculatory blood ﬂow or
the temperature of the hands [20].
5.2.2. Phosphodiesterase-5 Inhibitors. Phosphodiesterase-5
inhibitors (PDE5 inhibitors) induce vasodilatation by
increasing the levels of available endogenous nitric oxide
(NO). The positive eﬀect of sildenaﬁl on RP was shown
in a randomized controlled crossover study [21]a n dc a s e
reports and series indicate the beneﬁt of sildenaﬁl in SSc-
DUs [22, 23]. An open label pilot study using a maximum
dose of sildenaﬁl in 19 patients with SSc-DUs showed a total
r e d u c t i o no fu l c e r sf r o m4 9t o1 7( P<. 001) after 6 months
[24].
Shenoy et al. presented SSc-DUs healing results in a
crossover trial of tadalaﬁl [25]. The RP improvement was
clinically signiﬁcant, with a surprising absence of placebo
eﬀect. This is contradicted by another randomized crossover
trial of tadalaﬁl in SSc-RP which showed no beneﬁt of the
drug over placebo [26].
The role of PDE5 inhibitors in SSc-DUs needs to be
further evaluated in prospective, randomized trials.
5.2.3. Endothelin Receptor Antagonists. The endothelial
injury that is the hallmark of ischemic digital ulcers cor-
responds with an increase in levels of endothelin 1 (ET-1)
[27, 28]. ET-1 is a potent vasoconstrictor that mediates its
actions through two diﬀerent receptors: endothelin type A
(ET-A) receptors are found on vascular smooth muscle cells
while endothelin type B (ET-B) receptors are found on both
endothelial cells and vascular smooth muscle cells.
Bosentan is a receptor antagonist with activity against
both types of receptors, ET-A and ET-B. Anecdotal reports
and case series have suggested that bosentan may be
helpful in reducing ulcer size or improving healing [29–
31]. Other studies have demonstrated an improvement in
ﬂow-mediated dilatation of microvasculature with bosentan
therapy in patients with systemic sclerosis [32].
The RAPIDS-1 trial analyzed the eﬀect of Bosentan
on the prevention and treatment of existing digital ulcers
[3]. This randomized, placebo-controlled study of 122
patients with systemic sclerosis and preexisting digital ulcers
evaluated a primary outcome of bosentan on number of new
digital ulcers during a 16-week study period. Patients were
treated with bosentan 62.5mg twice daily for four weeks
then 125mg twice daily for 12 weeks. While no signiﬁcant
diﬀerence was seen in healing of existing ulcers, there were
signiﬁcant diﬀerences in hand function and number of new
ulcers in the treatment group (1.4 versus 2.7).
In the open-label extension of the study 88 patients
continued bosentan for 12 additional weeks (57 of these
patients were previously treated with bosentan for 16 weeks
and so received a total of 28 weeks of treatment) [33]. At the
end of the extension period, 65% of patients did not develop
any new digital ulcers while 8% (7 patients) developed more
than two new ulcers. The mean number of new DUs after
12 weeks of open-label therapy was 0.7 (all subjects), 0.5
(subjects previously on placebo), and 0.8 (previously on
bosentan). RAPIDS-2 was designed to conﬁrm the positive
eﬀects of bosentan at reducing new DUs in 188 patients with
at least an active SSc-DUs over a variable treatment course
[34]. Patients received 62.5mg bosentan twice daily for 4
w e e k st h e n1 2 5m gt w i c ed a i l yf o r2 0t o3 2w e e k s .N o n eo f
the measures of digital ulcer healing diﬀered between the
two groups (time to healing of a selected cardinal ulcer, time
to healing of all digital ulcers, and percent of patients with
complete healing). However, the total number of new ulcers
during a 24-week followup period was 1.9 on bosentan and
2.7 on placebo (P = .035). Unlike what is known of RP, there
was no clear inﬂuence of season on SSc-DUs, indicating that
DUs may be more related to the severity of vasculopathy.
Overall, oral bosentan at a dose of 125mg twice daily had
no eﬀect on ulcer healing in patients with digital ulcers and
SSc. Although bosentan seemed to have lessened the ulcer
burden in patients with more than four concomitant ulcers,
it had no eﬀect on RP.International Journal of Rheumatology 5
There are also anecdotal reports and case reports of
combination treatment with bosentan [35]. This case report
of a 73-year-old patient with systemic sclerosis reveals that
she was treated with both sildenaﬁl and bosentan which
resulted in complete healing of the digital ulcers.
Sitaxentan is a selective endothelin type A receptor
antagonist that has been reported to help heal SSc-DUs
in case reports [36], but no randomized clinical trials are
ongoing.
5.2.4. Prostacyclin Analogues. Prostacyclins are potent
vasodilators that also inhibit platelet aggregation and
smooth muscle proliferation in the blood vessels walls.
Various forms of prostacyclins are approved for use in
idiopathic and connective tissue-related pulmonary arterial
hypertension (PAH).
Epoprostenol is an intravenous prostanoid. In the pivotal
randomized controlled trial of epoprostenol in patients with
SSc-related PAH, the patients on epoprostenol had 50%
fewernew DUs than those treated with conventional therapy,
although no eﬀect on healing of the existing DUs was
reported [37].
Iloprost is the most studied prostacyclin analog and is
availableinintravenous(IV),oral,andinhaledformulations.
Outside the USA, cyclic use of intravenous iloprost is the
standard of care for treatment of ischemically threatened
digits and severe SSc-DUs. The most important clinical
trial supporting the use of iloprost was a 9-week, double-
blind placebo-controlled multicenter trial in patients with
SSc-RP [38]. In this trial, the intervention consisted of IV
iloprost 6-hours infusion (dose of 0.5–2ng/kg per minute)
for 5 days. A signiﬁcant proportion of the patients receiving
the active drug had at least 50% reduction in the number
of DUs. Interestingly, although the DUs healing was noted
at earlier time points, the eﬀect persisted at 9 weeks,
suggesting a potential “reset” eﬀect that iloprost might have
on the endothelium. In this particular trial, a trend towards
prevention of new DUs was noted. A randomized controlled
trial of oral iloprost at a ﬁxed dose for patients with SSc-RP
had negative results [39], most likely because there was no
titration to the maximum tolerated dose. Higher doses of
i l o p r o s tm a yb em o r ee ﬀective in SSc-RP at the expense of
increased side eﬀects [40].
Oral beraprost, another available prostacyclin analog,
was evaluated in a randomized controlled trial for SSc-RP
[41] and it showed a trend towards fewer new DUs in the
treatment group but no eﬀect of the RP.
Treprostinil is available in IV, subcutaneous, inhaled, and
oral formulations. A pilot study of subcutaneous treprostinil
in patients with SSc-DUs over a 12-week treatment period
showed both healing and prevention of the DUs but only a
few subjects were able to tolerate the injection site pain [42].
Treprostinil diethanolamine (TDE-SR) is an innovative salt
form of treprostinil for oral delivery as a sustained release
osmotic tablet for twice daily dosing. The pharmacokinetic
proﬁle of TDE-SR in patients with SSc-DUs is comparable
to that of healthy controls [43] despite a variable degree of
absorption related to SSc. An ongoing phase II randomized,
double blinded, multicenter clinical trial of oral treprostinil
in SSc-DUs is currently recruiting.
5.2.5.Statins. Itiswellrecognizedthatstatins(3-Hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors) have bene-
ﬁcial eﬀects on ischemic vascular events and consequences
of vascular injury [44]. An open-label study of 14 SSc
patients showed that 12 weeks of atorvastatin improved
the Raynaud’s severity and prevented new SSc-DUs [44].
A large randomized, double-blinded, placebo controlled
study of 84 patients with SSc and history of DUs showed
a signiﬁcant diﬀerence in the number of new DUs in the
treatment group compared to placebo over 4 months (1.6
versus2.5)[45].SigniﬁcantimprovementintheScleroderma
Health Assessment Questionnaire Disability Index (SHAQ-
DI) score and endothelial markers from the baseline was
noted.
5.2.6. Angiotensin-Converting Enzyme Inhibitors (ACEIs) and
Angiotensin Receptor Blockers (ARBs). The role of ACEI in
the management of scleroderma renal crisis has changed the
primary cause of mortality in SSc from renal to pulmonary
complications. ACE inhibition counteracts the renin-driven
hypertension but it also improves endothelial function and
promotes vascular remodeling in chronic hypertension.
A study of the long-acting ACEI, quinapril, used the rate
of occurrence of new DUs in patients with SSc as primary
outcome [46]. This was a multicenter, randomized, double-
blind, placebo-controlled study of quinapril at 20mg daily
for at least 2 years but not more than 3 years. Of the 213
patients enrolled, 109 patients were followed for the full 3
years.Attheendofthestudytherewasnodiﬀerencebetween
the treatment and the placebo group in the number of new
DUs, the total number of DUs, and measurements of RP
(frequency and severity). As the authors commented, the
lack of therapeutic eﬀect was not attributable to insuﬃcient
statistical power.
In a randomized 12-week trial comparing nifedipine to
losartan, an ARB, in patients with primary and secondary
RP (total number of patients of 52), losartan signiﬁcantly
reduced the RP severity and frequency [47]. This study
focused mainly on RPs and there was no mention of SSc-
DUs.
5.2.7. N-Acetylcysteine. N-acetylcysteine (NAC) is the pre-
cursor of a major antioxidant, glutathione, and may have
beneﬁcial eﬀects in SSc-DUs due to its vasodilating prop-
erties and impact on platelet aggregation. A pilot study of
intravenous NAC in 20 patients with SSc-DUs showed that
more than half of the DUs present at baseline completely
healed after the 5-day infusion [48]. A prospective observa-
tional study of intravenous NAC dosed at 15mg/kg/hr for 5
hours every 14 days was recently reported [49]. The median
treatment was 3 years, and the mean of ulcers/patient/year
decreased signiﬁcantly from 4.5 to 0.81 with minimal
reported side eﬀects. Although promising, in order to better
establish its use in SSc-DUs, this agent should be evaluated
in a prospective, placebo controlled, randomized fashion.6 International Journal of Rheumatology
5.2.8. Vitamin E Gel. Vitamin E has been used for chronic
cutaneous lesion and ulceration treatment based on its
antioxidant and anti-inﬂammatory eﬀects. An open-label
study of 27 patients with SSc-DUs randomly assigned 15
subjects to vitamin E gel. Patients treated with vitamin E
experienced signiﬁcantly reduced healing time (13.2 versus
20.0 weeks, P<. 0001) when compared to controls and
improved pain resolution (P = .0022).
5.3. Surgical Options. Surgical options are reserved for
treatment of severe or recurrent DUs that are recalcitrant
to medical therapy. Available procedures are microsurgical
revascularization of the hand and digital sympathectomy
[50]. Since the size of the blood vessels involved in the
pathogenesis of SSc-DUs is usually small, revascularization
is not readily applicable.
Sympathectomies are aiming to block the sympathetic
nerve-mediated vasospasm which is thought to have an
important role in digital ischemia. The long-term results
of cervical sympathectomy have been discouraging. Local
digital sympathectomy has the advantage of interrupting
the sympathetic ﬁber more distally. During digital sympa-
thectomy, the adventitia is excised, removing sympathetic
ﬁbers contained in the adventitia and most likely, the media.
This procedure has been shown to help healing of SSc-DUs,
improvementinpain,andpreventionofnewDUsforamean
of 31 months after the surgery [51]. The results of digital
sympathectomiesinpatientswithconnectivetissuedisorders
may not be as favorable as in patients with other diagnoses
[52].
Although the microvascular involvement in SSc is well
known, there are reports of macrovascular involvement as
well. A small study of 8 patients with DUs or gangrene
related to SSc found macrovascular involvement of the
ulnar artery (3 patients) and radial artery (1 patient) by
arteriography [53]. A larger retrospective study identiﬁed 12
(63.2%) of 19 patients with SSc who underwent brachial
arteriography to have ulnar artery involvement (occlusion
and/or stenosis) [54]. Potential for revascularization in
selected SSc patients with arteriographic evidence of ulnar
involvement was shown in a retrospective chart review [55]:
15 patients with SSc-DUs and ulnar artery occlusive disease
conﬁrmedbyangiographywerereviewed.Eightpatientswho
underwent ulnar revascularization combined with digital
sympathectomy had improvement in the healing of the
ulcers.
The current evidence is limited but there is a role for
brachial arteriography in selected patients with SSc-DUs to
diagnose macrovascular involvement. More interventional
trials are needed to assess the eﬃcacy of ulnar revasculariza-
tion in SSc-DUs prevention and treatment.
6. Conclusions
Digital ulcers aﬀect patients with SSc with a frequency of
30% per year. A precise deﬁnition of the SSc-DU would
be useful for the research community and also in clinical
practice. The eﬀect on function and quality of life of the
SSc-DU is signiﬁcant, so therapies focused on rapid healing
and prevention of new ulcers are needed. Although patients
note reduced pain and improved function when exposed to
parenteral agents like iloprost, the more subtle agents that
seem to be better at prevention (e.g., bosentan) oﬀer very
little beneﬁt on pain and quality of life. Important clinical
trials of oral or topical drugs with overall burden of the SSc-
D U sa sm a i no u t c o m em e a s u r ea r eo n g o i n g .
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